Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Harvard Business School
McKinsey
McKesson
Colorcon

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,856,346

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,856,346 protect, and when does it expire?

Patent 5,856,346 protects CLEVIPREX and is included in one NDA.

This patent has forty-one patent family members in thirty countries.

Summary for Patent: 5,856,346
Title: Short-acting dihydropyridines
Abstract:Compounds of the general formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, chloro, bromo, nitro, cyano, trifluoromethyl, and R.sub.3 and R.sub.4 are independently selected from straight or branched lower (1-5 carbon atoms) alkyl groups, and including all optical isomers, provided that when R.sub.3 is methyl and R.sub.4 is tert.-butyl, then R.sub.1 /R.sub.2 are not hydrogen/hydrogen, hydrogen/2'-trifluormethyl, 2'-chloro/3'-chloro, and when R.sub.3 is methyl and R.sub.1 /R.sub.2 is hydrogen/3'-nitro, then R.sub.4 are not methyl, ethyl, propyl, iso-propyl, tert.-butyl, processes for their preparation, pharmaceutical preparations containing them and the use of the compounds in lowering the blood pressure.
Inventor(s): Andersson; Kjell Hjalmar (Fjar.ang.s, SE), Nordlander; Margareta (Askim, SE), Westerlund; Rolf Christer (Molndal, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:08/356,224
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,856,346
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 5,856,346

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 RX Yes Yes   Start Trial   Start Trial Y Y CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE   Start Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 RX Yes Yes   Start Trial   Start Trial Y Y CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE   Start Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-003 Nov 8, 2013 DISCN Yes No   Start Trial   Start Trial Y Y CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,856,346

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9303657Nov 05, 1993
PCT Information
PCT FiledNovember 03, 1994PCT Application Number:PCT/SE94/01031
PCT Publication Date:May 11, 1995PCT Publication Number: WO95/12578

International Family Members for US Patent 5,856,346

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 194330   Start Trial
Australia 685532   Start Trial
Australia 8119694   Start Trial
Brazil 9407946   Start Trial
Canada 2174969   Start Trial
China 1049428   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKesson
Baxter
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.